GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BerGenBio ASA (LTS:0RU5) » Definitions » Investments And Advances

BerGenBio ASA (LTS:0RU5) Investments And Advances : kr0.00 Mil (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is BerGenBio ASA Investments And Advances?

BerGenBio ASA's Investments And Advances for the quarter that ended in Dec. 2024 was kr0.00 Mil.


BerGenBio ASA Investments And Advances Historical Data

The historical data trend for BerGenBio ASA's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BerGenBio ASA Investments And Advances Chart

BerGenBio ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Investments And Advances
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BerGenBio ASA Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

BerGenBio ASA Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


BerGenBio ASA Business Description

Traded in Other Exchanges
Address
Nygardsgaten 114, Bergen, NOR, 5008
BerGenBio ASA is a clinical-stage biopharmaceutical company developing drugs for aggressive diseases, including drug resistant and metastatic cancers and respiratory disease. Its product, bemcentinib (BGB324), is a selective, potent, oral small molecule AXL inhibitor that has been tested in a various indications including NSCLC, AML and severe respiratory infections.

BerGenBio ASA Headlines

No Headlines